2-氨基[1,2,4]噻唑并[1,5-a]吡啶 | 874-46-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: 2-氨基[1,2,4]噻唑并[1,5-a]吡啶
• 中文别名: [1,2,4]三唑并[1,5-A]吡啶-2-胺
• 英文名称: 2-amino-s-triazolo-<1,5-a>-pyridne
• 英文别名: [1,2,4]triazolo[1,5-a]pyridin-2-ylamine；2-amino-1,2,4-triazolo[1,5-a]pyridine；[1,2,4]triazolo[1,5-a]pyridin-2-amine；2-Amino-s-triazolo(1,5-a)pyridine；[1,2,4]triazolo[1,5-a]pyridin-2-ylamine；2-amino[1,2,4]triazolo[1,5-a]pyridine
• CAS: 874-46-4
• 化学式: C₆H₆N₄
• 分子量: 134.14
• InChiKey: PHTMVIAGTMTVSK-UHFFFAOYSA-N

物化性质

• 熔点：
  110-112℃
• 密度：
  1.50

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: [1,2,4]Triazolo[1,5-a]pyridin-2-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: [1,2,4]Triazolo[1,5-a]pyridin-2-amine
CAS number: 874-46-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6N4
Molecular weight: 134.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基[1,2,4]噻唑并[1,5-a]吡啶 在 盐酸 、 sodium nitrite 作用下， 以 水 、 乙腈 为溶剂， 以67%的产率得到2-氯-[1,2,4]三唑并[1,5-a]吡啶
  参考文献：
  名称：

  以N-吡啶-2-(1H)-腈亚氨为母核的荧光分子 及其制备与应用

  摘要：

  本发明提供了式(Ⅰ)所示化合物或其晶型、药学上可接受的盐。实验结果说明，本发明成功制备得到了以N‑吡啶‑2‑(1H)‑腈亚氨为母核的荧光分子，分子量小，易于修饰，量子产率较高，可作为荧光染料应用于洗衣粉中的增白剂、各种荧光路标漆等荧光染料产品的制备，此外还用于纤维织物印染和某些特殊标志的制作。本发明的荧光分子还可在科研中用于荧光免疫、荧光探针、细胞染色等，包括特异性的DNA染色，用于染色体分析、细胞周期、细胞凋亡等相关研究。

  公开号：

  CN108715584B
• 作为产物：
  描述：

  N-ethoxycarbonyl-N'-(pyridin-2-yl)tiourea 在 盐酸羟胺 、 三乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 2-氨基[1,2,4]噻唑并[1,5-a]吡啶
  参考文献：
  名称：

  一种基于三唑并吡啶的有机电致发光材料及有机电致发光器件

  摘要：

  本发明涉及光电材料应用科技领域，公开了一种基于三唑并吡啶的有机电致发光材料及有机电致发光器件。该有机电致发光材料通过特定官能团对三唑并吡啶基团的精细调控，提供了一种综合性能优良电子传输材料和发光主体材料，有效解决现有技术中电子传输材料与空穴传输速率不匹配、稳定性差的技术问题，以及绿光主体材料器件效率降滚、光色不纯的技术问题，进而提高器件在驱动电压、效率、光色、热稳定性、寿命等方面的综合性能，加快光电材料产业化发展进程。

  公开号：

  CN110452689B

文献信息

• [EN] GAMMA SECRETASE MODULATERS<br/>[FR] MODULATEURS DE GAMMA-SECRÉTASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011092272A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of formula ( I ) wherein R1/R1' are independently from each other hydrogen, halogen, lower alkoxy or cyano; R2 is lower alkyl, halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by OR, =0, -C(O)O-lower alkyl, -C(O)NH-lower alkyl, cyano, CH2-O-lower alkyl, cycloalkyl, NRR'or is -O-(CH2)o-phenyl optionally substituted by halogen, or is -(CH2)o-phenyl optionally substituted by one, two or three substituents, selected from halogen, -(CH2)o-cyano, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, C(O)H, -CH2-NH2-, -CH2-NH-C(O)O-lower alkyl, -CH2-NH-C(O)-lower alkyl, -CH2-NH-lower alkyl, -CH2-NH-S(O)2-lower alkyl, lower alkoxy or by lower alkoxy substituted by halogen, or is -(CH2)o-cycloalkyl, or is -(CH2)o-heterocycloalkyl which is optionally substituted by halogen, CF3, lower alkyl, -CH2CN, -C(O)-lower alkyl, -C(O)O-lower alkyl or S(O)2-lower alkyl, or is heteroaryl selected from the group consisting of furanyl, pyrazinyl, pyridinyl, benzooxazolyl or benzoimidazolyl which are optionally substituted by lower alkyl, or is 4-methyl-3,4-dihydro-2H-benzo[l,4]oxazine R and R' are independently from each other hydrogen or lower alkyl, and o is 0 or 1; R3 may occur once or twice and is lower alkyl; A is Formula a), b), c), d), e), f), h), i), j) and Formula k); R2' is hydrogen, lower alkyl, lower alkyl substituted by halogen, C(O)-lower alkyl, S(O)2-lower alkyl or phenyl optionally substituted by halogen; hetaryl is a 5 or 6 membered N, S or O-containing heteroaryl group; n is O, 1, 2 or 3; if n is 2 or 3, R2 may be the same or not; or to pharmaceutically active acid addition salts thereof. The present compounds of formula ( I ) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi- infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式（I）的化合物，其中R1/R1'分别独立地为氢、卤素、较低的烷氧基或氰基；R2为较低的烷基、卤素、较低的烷氧基、卤素取代的较低烷基、卤素取代的较低烷氧基、取代的较低烷基OR、=0、-C(O)O-较低烷基、-C(O)NH-较低烷基、氰基、CH2-O-较低烷基、环烷基、NRR'或为-O-(CH2)o-苯基，可选择地取代为卤素，或为-(CH2)o-苯基，可选择地取代为一个、两个或三个取代基，选自卤素、-(CH2)o-氰基、较低烷基、卤素取代的较低烷基、羟基取代的较低烷基、C(O)H、-CH2-NH2-、-CH2-NH-C(O)O-较低烷基、-CH2-NH-C(O)-较低烷基、-CH2-NH-较低烷基、-CH2-NH-S(O)2-较低烷基、较低烷氧基或取代的较低烷氧基，或为-(CH2)o-环烷基，或为-(CH2)o-杂环烷基，可选择地取代为卤素、CF3、较低烷基、-CH2CN、-C(O)-较低烷基、-C(O)O-较低烷基或S(O)2-较低烷基，或为杂芳基，选自呋喃基、吡嗪基、吡啶基、苯并噁唑基或苯并咪唑基，可选择地取代为较低烷基，或为4-甲基-3,4-二氢-2H-苯并[l,4]噁啉，R和R'分别独立地为氢或较低烷基，o为0或1；R3可能出现一次或两次，为较低烷基；A为式a)、b)、c)、d)、e)、f)、h)、i)、j)和式k)；R2'为氢、较低烷基、卤素取代的较低烷基、C(O)-较低烷基、S(O)2-较低烷基或可选择地取代为卤素的苯基；hetaryl为5或6成员的含氮、硫或氧的杂芳基；n为O、1、2或3；如果n为2或3，R2可能相同也可能不同；或其药用活性酸盐。该式（I）的化合物是淀粉样蛋白β的调节剂，因此，它们可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、遗传性淀粉样脑出血症，荷兰型（HCHWA-D），多梗死性痴呆、拳击性痴呆和唐氏综合征。
• 一种基于三唑并吡啶的有机电致发光材料及 有机电致发光器件
  申请人：武汉尚赛光电科技有限公司

  公开号：CN110590770B

  公开（公告）日：2020-12-25

  本发明涉及光电材料应用科技领域，公开了一种基于三唑并吡啶的有机电致发光材料及有机电致发光器件。该有机电致发光材料通过特定官能团对三唑并吡啶基团的精细调控，提供了一种综合性能优良的发光主体材料和电子传输材料，有效解决现有技术中双极性主体材料作为发光主体材料时与掺杂剂之间能量回传的问题以及芳香三嗪型等发光主体材料激发态寿命相对较长引起的效率降滚问题，解决器件内电子传输和空穴阻挡能力参差不齐,导致器件的性能差异很大的问题，加快光电材料产业化发展进程。
• [EN] HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BetaEpsilonTauAlpha-LACTAMASE INHIBITORS<br/>[FR] DERIVES D'HETEROTRICYCLYL 6-ALKYLIDENE-PENEMES EN TANT QU'INHIBITEURS DE BETA-LACTAMASE
  申请人：WYETH CORP

  公开号：WO2003093280A1

  公开（公告）日：2003-11-13

  The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.

  本发明提供了一种I式化合物，药物组合物以及其用于治疗患有细菌感染或疾病的患者的用途。
• [EN] THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS AMINOHÉTÉROARYLE À SUBSTITUTION THIAZOLE UTILISÉS COMME INHIBITEURS DE LA TYROSINE KINASE SPLÉNIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095444A1

  公开（公告）日：2015-06-25

  The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) (I), or pharmaceutically acceptable salts thereof, wherein ring R1, R2, R3, R4, ring A, and the subscripts n1, n2, and r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).

  该发明提供了某些噻唑取代氨基杂环芳烃化合物的化学式(I) (I)，或其药用可接受的盐，其中环R1、R2、R3、R4、环A以及下标n1、n2和r如本文所定义。该发明还提供了包含这些化合物的药物组合物，以及利用这些化合物治疗由脾酪氨酸激酶（Syk）介导的疾病或症状的方法。
• [EN] BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS<br/>[FR] INHIBITEURS DE BRD4-KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：H LEE MOFFITT CANCER CENTER & RES INST INC

  公开号：WO2017066428A1

  公开（公告）日：2017-04-20

  Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

  本文披露了一些抑制BDR4的化合物及其在癌症治疗中的应用。还披露了筛选BDR4选择性抑制剂的方法。在某些方面，披露了公式I至IV的化合物。